Jyothy Laboratories reported a significant decline in profitability for the quarter ended June 30, 2026, as net profit after tax fell 51% year-on-year to ₹47.64 crore. Despite a modest increase in top-line growth, the company’s earnings per share (EPS) dropped to ₹1.30, down from ₹2.64 in the same period last year.

The Board of Directors, chaired by Ms. M. R. Jyothy, approved the unaudited financial results at a meeting held on August 12, 2026. The results were reviewed by the Audit Committee prior to approval.

Financial Performance Overview

Revenue from operations rose 3% year-on-year to ₹773.4 crore, up from ₹751.21 crore in Q1FY25. However, this revenue growth did not translate into proportional profit expansion. Net profit before tax declined 49% to ₹64.98 crore from ₹127.53 crore in the corresponding quarter of the previous fiscal year.

On a sequential basis, the results also showed a downturn compared to the immediately preceding quarter (Q4FY26). Revenue increased slightly to ₹773.4 crore from ₹717.41 crore, but net profit after tax fell 29% to ₹47.64 crore from ₹67.52 crore.

What the Numbers Show

The divergence between revenue growth and profit contraction highlights severe margin compression during the quarter. While sales expanded by approximately ₹22.19 crore year-on-year, net profit before tax nearly halved. This suggests that cost structures or input prices may have risen disproportionately to revenue generation, eroding operational efficiency. The effective tax rate remained stable at approximately 27%, indicating that the profit decline was driven primarily by pre-tax operational factors rather than tax regime changes.

Segment Reporting Update

The company revised its internal management segment reporting structure during the quarter. The Chief Operating Decision Maker now reviews the business under three reportable segments: Fabric Care, Home Care, and Personal Care. Comparative segment information for previous periods has been restated accordingly, though these restated figures have not been subjected to limited review or audit.

Jyothy Laboratories expects steady margin recovery tied to sales growth, with benefits from lower crude costs projected to materialize gradually from October, provided prices remain stable. The company aims for high single-digit volume growth this year, supported by 3-4% price increases, to reach historical margin levels linked to crude prices.

Management forecasts double-digit revenue growth for FY27 without the Pril business. However, EBITDA margins may face pressure from high crude-linked costs in the near term. The second half of the fiscal year is expected to improve compared to the first half, driven by better demand and favorable commodity price movements.

Strategic Outlook

The company’s strategy relies on balancing volume expansion with selective pricing power. Key operational targets include:

• Volume Growth: High single-digit percentage increase.
• Price Hikes: 3-4% increases planned.
• Revenue Target: Double-digit growth for FY27 (excluding Pril).
• Margin Recovery: Expected from October, contingent on stable crude prices.

What the Numbers Show

The divergence between the volume growth target and the price increase strategy suggests a focus on market share retention while attempting to offset input cost inflation. With EBITDA margins facing pressure from high crude-linked costs, the reliance on October-onset cost benefits indicates a lagged impact of commodity cycles on profitability. The exclusion of the Pril business from the double-digit revenue growth forecast highlights a structural shift in the company’s core earnings base.

The second-half improvement expectation underscores the sensitivity of margins to commodity prices, implying that H1FY27 results may reflect the peak of current cost pressures before easing trends take hold.